Surgery	O

Trabeculectomy	O
should	O
be	O
considered	O
in	O
all	O
patients	O
,	O
when	O
the	O
'	O
target	O
IOP	O
'	O
is	O
not	O
achieved	O
with	O
glaucoma	B-Pathological_formation
medications	O
and	O
if	O
the	O
expected	O
rate	O
of	O
visual	O
loss	O
could	O
affect	O
the	O
patient	O
during	O
their	O
lifetime	O
.	O

In	O
this	O
procedure	O
,	O
an	O
opening	O
is	O
made	O
in	O
the	O
trabecular	B-Organ
meshwork	O
,	O
so	O
that	O
aqueous	B-Organism_substance
humor	I-Organism_substance
can	O
drain	O
into	O
the	O
sclera	B-Multi-tissue_structure
.	O

Many	O
patients	O
can	O
discontinue	O
glaucoma	B-Pathological_formation
medications	O
after	O
surgery	O
.	O

Approximately	O
one	O
-	O
third	O
of	O
the	O
trabeculectomy	O
patients	O
develop	O
cataract	O
within	O
five	O
years	O
.	O

If	O
trabeculectomy	O
fails	O
,	O
another	O
type	O
of	O
surgery	O
places	O
a	O
drainage	O
tube	O
(	O
Molteno	O
tube	O
)	O
in	O
the	O
eye	B-Organ
,	O
between	O
the	O
cornea	B-Multi-tissue_structure
and	O
iris	B-Multi-tissue_structure
,	O
which	O
exits	O
at	O
the	O
junction	O
of	O
the	O
cornea	B-Multi-tissue_structure
and	O
sclera	B-Multi-tissue_structure
.	O

Cyclodestructive	O
procedures	O
,	O
which	O
lower	O
IOP	O
by	O
destroying	O
the	O
ciliary	B-Multi-tissue_structure
body	I-Multi-tissue_structure
,	O
are	O
typically	O
reserved	O
for	O
eyes	B-Organ
,	O
which	O
are	O
refractory	O
to	O
all	O
other	O
forms	O
of	O
therapy	O
.	O

These	O
procedures	O
include	O
cyclocryotherapy	O
,	O
cylcodiathermy	O
and	O
laser	O
cyclophotocoagulation	O
.	O
[	O
91	O
-	O
93	O
]	O

